A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2017
Price : $35 *
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Alkermes plc
- 13 Jul 2016 Status changed from recruiting to completed.
- 15 Jul 2013 New trial record
- 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.